Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
NCT06741228 is registered in ClinicalTrials.gov with Definium Therapeutics US, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
- Lead sponsor
- Definium Therapeutics US, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 11, 2024
- Completion date
- April 30, 2027
- Enrollment
- 214 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.